Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 1

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 1
---
 acted upon:

| 1. | the election of seven (7) directors, nominated by the Company’s Board of Directors, to serve until the Company’s annual meeting of shareholders to be held in 2026 or until their successors are duly elected and qualified;                                                                                                                                                                                             |
| 2. | the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers as described in this proxy statement;                                                                                                                                                                                                                                                                        |
| 3. | the approval of an amendment to the Company’s 2019 Equity Incentive Compensation Plan (the “2019 Plan”) to (i) increase the number of shares available for issuance under the 2019 Plan by 1,725,000 shares, (ii) remove the 2019 Plan’s “fungible share pool” provisions (as described herein) and (iii) increase the number of shares issuable under the 2019 Plan as incentive stock options from 171,429 to 300,000; |
| 4. | the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the fiscal year ending September 30, 2025; and                                                                                                                                                                                                                                                                |
| 5. | such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.                                                                                                                                                                                                                                                                                                         |

Only shareholders of record at the close of business on March 31, 2025, are entitled to receive notice of, and to vote at, the Annual Meeting and any adjournments or postponements thereof.

Your vote is important. To assure your representation at the Annual Meeting, you are urged to sign, date and return the proxy as soon as possible, or follow the instructions contained in the Notice of Internet Availability of Proxy Materials to vote by telephone or on the Internet. You may vote in person at the Annual Meeting even if you have previously returned a proxy. You may revoke your proxy in the manner described in the proxy statement at any time before it has been voted at the Annual Meeting.

By Order of the Board of Directors

/s/Pardeep Nijhawan

Pardeep Nijhawan, MD

Director, Chief Executive Officer and Corporate Secretary

(Principal Executive Officer)

April 4, 2025

Markham, ON, Canada

<div align='center'>TABLE OF CONTENTS</div>

| ABOUT THE MEETING                                              |     1 |
| PROPOSAL 1                                                     |     7 |
| CORPORATE GOVERNANCE                                           |